ReviewOrphanet journal of rare diseases2025
Progress of iPSC-derived retinal organoids in the study of inherited retinal diseases.
Review in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Restorative and regenerative therapies for vision loss.Eye (London, England) · 2026Review
- Induced pluripotent stem cell reprogramming: methodological evolution and challenges in clinical translation.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Inherited retinal diseases (IRDs) constitute a complex and heterogeneous group of rare disorders characterized by significant genetic diversity. These conditions often lead to the degeneration of photoreceptor cells, resulting in severe visual impairment. A major challenge in the study and treatment of IRDs is the lack of appropriate preclinical models for investigating their pathogenesis and evaluating potential therapeutic interventions. In recent years, advances in retinal organoids (ROs) culture technology have provided promising new avenues for IRDs. This review systematically elaborates on the applications of induced pluripotent stem cells (iPSC)-derived ROs as disease models in IRDs such as retinoblastoma (RB), retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and X-linked juvenile retinoschisis (XLRS). This review also briefly explores the culturing methods of iPSC-derived ROs in recent years. Specifically, it emphasizes the comparison of the similarities between the formation process of ROs and the in-vivo retinal development process. This encompasses aspects such as the formation of different structures, the expression of key markers, and the manifestation of physiological functions. By utilizing the RO disease model to explore the pathogenesis of IRDs and conduct drug screening, it is expected to advance the precision treatment of IRDs and improve the therapeutic outcomes for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.